Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Auswirkungen von Lactobacillus Plantarum PS128 bei Kindern mit ASD

14. September 2026 aktualisiert von: Chang Gung Memorial Hospital

Auswirkungen von Lactobacillus Plantarum PS128 bei Kindern mit Autismus-Spektrum-Störung

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

41

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Taoyuan, Taiwan
        • Chang Gung Memorial Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

7 Jahre bis 12 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • (1) Age 7 to 12 years old.
  • (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
  • (3) Normal control group: Children without autism spectrum disorder.

Exclusion Criteria:

  • (1) Receiving antibiotics within one month.
  • (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
  • (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
  • (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
  • (5) Those with a history of cancer.
  • (6) Those who are allergic to lactic acid bacteria.
  • (7) Not eligible judged by PI

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: PS128

Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.

Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.

Placebo-Komparator: Placebo

Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.

The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.

Kein Eingriff: Normal control

Normal control group are enrolled by invitation from the age and gender matched healthy children.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes of Total Scores of Social Responsiveness Scale
Zeitfenster: Baseline, Week 12 and Week 16

Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

Baseline, Week 12 and Week 16

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes of Total Scores of Repetitive Behavior Scale-Revised
Zeitfenster: Baseline, Week 12 and Week 16

Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Child Behavior Checklist
Zeitfenster: Baseline, Week 12 and Week 16

Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Adaptive Behavior Assessment System
Zeitfenster: Baseline, week 12 and Week 16

Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.

Baseline, week 12 and Week 16
Changes in Accuracy of Frith-Happe Animation
Zeitfenster: Baseline, Week 12 and Week 16

A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.

Baseline, Week 12 and Week 16
Changes in Accuracy of Eyes Task
Zeitfenster: Baseline, Week 12 and Week 16

An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.

Baseline, Week 12 and Week 16
Changes of Total Scores of Aberrant Behavior Checklist
Zeitfenster: Baseline, Week 12 and Week 16

Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Emotional Dysregulation Inventory
Zeitfenster: Baseline, Week 12 and Week 16

Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Zeitfenster: Baseline, Week 12 and Week 16

Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress.

Baseline, Week 12 and Week 16
Assessment of Clinical Global Impression-Severity of Illness
Zeitfenster: Week 12 and Week 16

The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.

Week 12 and Week 16
Assessment of Patient Global Impression of Change
Zeitfenster: Week 12 and Week 16

The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)."

Week 12 and Week 16
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Zeitfenster: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota

Baseline and Week 12
MRI T1
Zeitfenster: Baseline and Week 12

Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Zeitfenster: Baseline and Week 12

Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Diffusion Tensor Imaging (DTI) - FA
Zeitfenster: Baseline and Week 12

Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Safety Assessment - Albumin
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl).

Baseline and Week 12
Safety Assessment - Total Protein
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl).

Baseline and Week 12
Safety Assessment - ALP
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALP (135-320 U/L).

Baseline and Week 12
Safety Assessment - Total Bilirubin
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl).

Baseline and Week 12
Safety Assessment - T-Cholesterol
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).

Baseline and Week 12
Safety Assessment - Uric Acid
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl).

Baseline and Week 12
Safety Assessment - BUN
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl).

Baseline and Week 12
Safety Assessment - Creatinine
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl).

Baseline and Week 12
Safety Assessment - AST
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as AST (13-40 U/L).

Baseline and Week 12
Safety Assessment - ALT
Zeitfenster: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALT (7-40 U/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Zeitfenster: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Zeitfenster: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Zeitfenster: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Zeitfenster: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Zeitfenster: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Zeitfenster: Baseline and Week 12

Oxidative stress is assessed via Serotonin (ng/mL).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Zeitfenster: Baseline and Week 12

Oxidative stress is assessed via GABA (μmol/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Zeitfenster: Baseline and Week 12

Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl).

Baseline and Week 12
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Zeitfenster: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota.

Baseline and Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Juli 2022

Primärer Abschluss (Tatsächlich)

3. April 2024

Studienabschluss (Tatsächlich)

3. April 2024

Studienanmeldedaten

Zuerst eingereicht

14. März 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

24. März 2022

Zuerst gepostet (Tatsächlich)

1. April 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. September 2026

Zuletzt verifiziert

1. Februar 2025

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 202101416A3

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .